Good morning :)
$
₹
Omeros Corporation

Omeros Corporation

OMER

NASDAQ
Asset Logo

Omeros Corporation

OMER

NASDAQ
$16.910.89% (-0.15)
$
₹
$16.910.89% (-0.15)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $1.3B the stock is ranked 2520

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

14.90
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.83
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$1.22
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.80
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

324.88%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 3 analysts reports

Buy
2 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+62.53%

Earnings Growth

+133.72%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
45.74
45.74
1Y Return
44.64%
44.64%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
41.93
41.93
1Y Return
48.67%
48.67%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
151.87
151.87
1Y Return
71.05%
71.05%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
31.48
31.48
1Y Return
28.42%
28.42%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.73
26.73
1Y Return
10.56%
10.56%
Buy Reco %
75.00
75.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 62.53% growth, versus a trailing 3-year CAGR of 131.71%.

2026
Current$16.92Baseline
Analyst Target - 1 year
Target$27.5+62.53%

All values in $

202220232024202520262027$9.09$16.14$23.20Target+62.53%
2026
Current$16.92Baseline
Analyst Target - 1 year
Target$27.5+62.53%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$0Baseline
Forecast for Dec 2026
High$151.1
Average$127.5
Low$103.1

All values in $ Million

20212022202320242025202690.520000LowAverageHigh
2025
Current$0Baseline
Forecast for Dec 2026
High$151.1
Average$127.5
Low$103.1

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-2.05Baseline
Forecast for Dec 2026
High$0.88+143%
Average$0.69+133.72%
Low$0.5+124.43%

All values in $

202120222023202420252026-1.76-0.01-2.3-3.06-2.05Low+124.43%Average+133.72%High+143%
2025
Current$-2.05Baseline
Forecast for Dec 2026
High$0.88+143%
Average$0.69+133.72%
Low$0.5+124.43%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-30.9
86.4
9.8
56
28.5
13.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue1.360000.410009.8928.52
Net Income-37.18-56.04-32.23-31.35-33.46-25.42-30.9186.4556.0613.23
Net Profit Margin-2722.10%----8121.35%---566.66%46.38%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Omeros Corporation 14.903.830.80
Eli Lilly and Company45.7431.171.32
Johnson & Johnson41.937.852.99
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare OMER with any stock or ETF
Compare OMER with any stock or ETF
Comparing from
OMER
LLY
JNJ
Loading...

Frequently asked questions

  1. Omeros Corporation (OMER) share price today is $16.91 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $17.26 and a day low of $16.65.

  2. Omeros Corporation stock trades on NASDAQ under the ticker symbol OMER.

  3. Omeros Corporation's market capitalization is $1.31B as of November 7, 2026 at 2:29 AM IST.

  4. Omeros Corporation's price-to-earnings (P/E) ratio is 14.90 as of November 7, 2026.

  5. Omeros Corporation's price-to-book (P/B) ratio is 3.83 as of November 7, 2026.

  6. Yes, You can buy Omeros Corporation shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Omeros Corporation shares in three steps: 1. Search Omeros Corporation on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Omeros Corporation trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Omeros Corporation (OMER) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.5911 shares at the current price of $16.91.

Loading...